Multiply Labs announced a $75 million Series B on Oct. 6, 2026 in San Francisco. The round was led by Dr.
Patrick Soon-Shiong with NantWorks. Multiply Labs builds robotic clusters for biologics manufacturing. The systems automate timed, repetitive steps inside an enclosed unit that works with existing instruments.
Table of Contents
- How the robotic clusters fit drug plants
- Who joined the $75 million round
- Why manual biomanufacturing limits capacity
- What the funding will do, and its limits
How the robotic clusters fit drug plants
The clusters run production steps inside an enclosed, GMP-compliant system. GMP means the setup follows controlled manufacturing practices for medicines. The design integrates with instruments a facility already uses.
It does not require a new facility, according to Multiply Labs in the company announcement. Pharmaceutical companies own and operate the systems directly. The model is in-house automation rather than outsourced manufacturing.
Who joined the $75 million round
New investors were AstraZeneca, Lingotto, Teradyne and Strange Ventures. Returning investors included Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund, as reported by Multiply Labs via Business Wire in the financing report. Soon-Shiong said robotic manufacturing could change the speed and scale of cell therapies worldwide.
The round brings total capital raised since the 2016 founding to over $100 million. Teradyne's presence links the round to established automation expertise. AstraZeneca's presence links it to a large drug manufacturer.
Why manual biomanufacturing limits capacity
Manual biomanufacturing constrains capacity for complex therapies. Patients awaiting those therapies and drug manufacturers feel that constraint. Contamination events can cost millions.
Robotics aims to reduce contamination and increase throughput. The platform started with cell and gene therapy. It is expanding to antibodies, viral vectors and mRNA.
What the funding will do, and its limits
Multiply Labs says the funding will expand manufacturing capacity and advance its product roadmap. It will also grow engineering, regulatory and commercial teams to deliver more AI-designed therapies at scale, according to Pulse 2.0 in the scale-up report. Readers should treat efficiency figures as company claims:.
- 74% lower cost per dose is company-reported, not independently verified
- Up to 100x manual throughput is company-reported, not independently verified
- Actual results will depend on therapy type, plant setup and validation
